OBJECTIVE: A cavum between the septi pellucidi may reflect neurodevelopmental anomalies in midline structures of the brain. The authors examined cavum septi pellucidi in subjects with schizophrenia, affective disorder, and schizotypal personality disorder and in normal subjects. METHOD: Thirty schizophrenic patients (15 chronic, 15 first-episode), 16 patients with affective disorder (first-episode), 21 patients with schizotypal personality disorder, and 46 normal subjects were evaluated with magnetic resonance imaging. Cavum septi pellucidi was assessed by counting the number of 1.5-mm slices containing cavum septi pellucidi. RESULTS: The presence or absence of cavum septi pellucidi did not differentiate among groups. However, the prevalence of abnormal cavum septi pellucidi (i.e., cavum septi pellucidi contained on four or more slices) was 30.4% for schizophrenic patients (36.4% for chronic, 25.0% for first-episode), 20.0% for patients with affective disorder, 18.8% for patients with schizotypal personality disorder, and 10.3% for normal subjects. When the authors used the Nopoulos et al. criteria for rating cavum septi pellucidi, which omitted borderline cases with cavum septi pellucidi on three slices, the prevalence of abnormal cavum septi pellucidi increased to 35.0% for schizophrenia (40.0% for chronic, 30.0% for first-episode), 25.0% for affective disorder, 27.3% for schizotypal personality disorder, and 13.0% for normal subjects. There was a statistically significant difference in ratings between schizophrenic and normal subjects. CONCLUSIONS: The results suggest that alterations in midline structures during the course of neurodevelopment may play a role in the pathogenesis of schizophrenia.
OBJECTIVE: A cavum between the septi pellucidi may reflect neurodevelopmental anomalies in midline structures of the brain. The authors examined cavum septi pellucidi in subjects with schizophrenia, affective disorder, and schizotypal personality disorder and in normal subjects. METHOD: Thirty schizophrenicpatients (15 chronic, 15 first-episode), 16 patients with affective disorder (first-episode), 21 patients with schizotypal personality disorder, and 46 normal subjects were evaluated with magnetic resonance imaging. Cavum septi pellucidi was assessed by counting the number of 1.5-mm slices containing cavum septi pellucidi. RESULTS: The presence or absence of cavum septi pellucidi did not differentiate among groups. However, the prevalence of abnormal cavum septi pellucidi (i.e., cavum septi pellucidi contained on four or more slices) was 30.4% for schizophrenicpatients (36.4% for chronic, 25.0% for first-episode), 20.0% for patients with affective disorder, 18.8% for patients with schizotypal personality disorder, and 10.3% for normal subjects. When the authors used the Nopoulos et al. criteria for rating cavum septi pellucidi, which omitted borderline cases with cavum septi pellucidi on three slices, the prevalence of abnormal cavum septi pellucidi increased to 35.0% for schizophrenia (40.0% for chronic, 30.0% for first-episode), 25.0% for affective disorder, 27.3% for schizotypal personality disorder, and 13.0% for normal subjects. There was a statistically significant difference in ratings between schizophrenic and normal subjects. CONCLUSIONS: The results suggest that alterations in midline structures during the course of neurodevelopment may play a role in the pathogenesis of schizophrenia.
Authors: R W McCarley; C G Wible; M Frumin; Y Hirayasu; J J Levitt; I A Fischer; M E Shenton Journal: Biol Psychiatry Date: 1999-05-01 Impact factor: 13.382
Authors: Chandlee C Dickey; Robert W McCarley; Martina M Voglmaier; Melissa Frumin; Margaret A Niznikiewicz; Yoshio Hirayasu; Stephanie Fraone; Larry J Seidman; Martha E Shenton Journal: Am J Psychiatry Date: 2002-09 Impact factor: 18.112
Authors: Flavia S May; Q Cece Chen; Mark W Gilbertson; Martha E Shenton; Roger K Pitman Journal: Biol Psychiatry Date: 2004-03-15 Impact factor: 13.382
Authors: Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou Journal: Int J Dev Neurosci Date: 2010-10-08 Impact factor: 2.457
Authors: Inga K Koerte; Jakob Hufschmidt; Marc Muehlmann; Yorghos Tripodis; Julie M Stamm; Ofer Pasternak; Michelle Y Giwerc; Michael J Coleman; Christine M Baugh; Nathan G Fritts; Florian Heinen; Alexander Lin; Robert A Stern; Martha E Shenton Journal: J Neurotrauma Date: 2015-12-15 Impact factor: 5.269
Authors: Dana Crooks; Nathaniel E Anderson; Matthew Widdows; Nia Petseva; Michael Koenigs; Charles Pluto; Kent A Kiehl Journal: Neuropsychologia Date: 2018-03-12 Impact factor: 3.139